Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last CNY29.15 CNY
Change Today +0.15 / 0.52%
Volume 14.8M
As of 3:00 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

harbin gloria pharmaceutic-a (002437) Snapshot

Open
CNY27.61
Previous Close
CNY29.00
Day High
CNY31.00
Day Low
CNY26.20
52 Week High
06/3/15 - CNY45.32
52 Week Low
08/27/14 - CNY20.36
Market Cap
21.3B
Average Volume 10 Days
15.7M
EPS TTM
CNY0.71
Shares Outstanding
731.9M
EX-Date
05/8/15
P/E TM
41.2x
Dividend
CNY0.10
Dividend Yield
0.34%
Current Stock Chart for HARBIN GLORIA PHARMACEUTIC-A (002437)

Related News

No related news articles were found.

harbin gloria pharmaceutic-a (002437) Related Businessweek News

No Related Businessweek News Found

harbin gloria pharmaceutic-a (002437) Details

Harbin Gloria Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products primarily in the People’s Republic of China. The company offers orthopedic medicines, antineoplastic products, medical-nutrition products, rheumatology drugs, digestive and respiratory system medicines, cardiovascular medicines, liver disease medications, gynecology medications, and antibiotics. It also provides circulatory system, pediatrics, uropoiesis and reproduction, immune regulation, and other products. Harbin Gloria Pharmaceuticals Co., Ltd. was founded in 2000 and is based in Harbin, the People’s Republic of China.

Founded in 2000

harbin gloria pharmaceutic-a (002437) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

harbin gloria pharmaceutic-a (002437) Key Developments

Harbin Gloria Pharmaceuticals Co., Ltd(SZSE:002437) added to Shenzhen Stock Exchange Component A Share Index

Harbin Gloria Pharmaceuticals Co., Ltd has been added to Shenzhen Stock Exchange Component A Share Index.

Harbin Gloria Pharmaceuticals Co., Ltd(SZSE:002437) added to Shenzhen Stock Exchange Component Index

Harbin Gloria Pharmaceuticals Co., Ltd has been added to Shenzhen Stock Exchange Component Index.

Sucampo Pharmaceuticals and Harbin Gloria Pharmaceuticals Co Announce AMITIZA (Lubiprostone) Partnership in China

Sucampo Pharmaceuticals revealed the execution of an exclusive license, development, commercialization and supply agreement for AMITIZA (lubiprostone) in China in partnership with Harbin Gloria Pharmaceuticals Co. This agreement provides Gloria with the rights to develop and commercialize Sucampo's AMITIZA in China, subject to regulatory approval of the product by the China Food and Drug dministration (CFDA). Under the terms of the agreement, Sucampo will receive an upfront payment of USD 1.5 million. The upfront payment will consist of USD 1 million within 30 days of signing the agreement and USD 500,000 within 30 days of investigational new drug application approval in China. In conjunction, Sucampo will be eligible for an additional milestone payment upon the occurrence of a regulatory or alternatively a commercial milestone event. It will be the exclusive supplier of AMITIZA to Gloria at an agreed-upon supply price. The term of this agreement is 13 years with renewal terms. Additionally, Gloria will be responsible for all development activities and costs as well as all commercialization and regulatory activities in China.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
002437:CH CNY29.15 CNY +0.15

002437 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 002437.
View Industry Companies
 

Industry Analysis

002437

Industry Average

Valuation 002437 Industry Range
Price/Earnings 42.9x
Price/Sales 10.4x
Price/Book 7.0x
Price/Cash Flow 44.1x
TEV/Sales 9.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HARBIN GLORIA PHARMACEUTIC-A, please visit www.gloria.cc. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.